MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'flibanserin'. Sat, 03 Sep 2011 02:54:37 +0100 http://www.medworm.com/index.php?rid=4082331&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F1PftGII3ISA%2F Earlier this year, Boehringer ingelheim helped reignite controversy over female sexual dysfunction – whether Hypoactive Sexual Desire Disorder is truly a disorder and the extent to which medication may be a feasible solution - with an aggressive marketing plan for a pill called flibanserin. The episode encapsulated the debate over medicine versus marketing and occurred during a run-up to a closely watched FDA advisory committee meeting this past summer in which the drugmaker failed to win a recommendation (look here). Since then, Boehringer ditched plans to seek FDA approval (see this). And so we spoke with Ray Moynihan, an Australian journalist, who recently published a book called ‘Sex, Lies & Pharmaceuticals’ and has written extensively on this issue, about any lessons learne... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4082331 Tue, 19 Oct 2010 12:14:41 +0100 4082331 http://www.medworm.com/index.php?rid=3676895&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F2XOY_lJHta0%2F After weeks of anticipation and debate, an FDA advisory committee decided a Boehringer Ingelhim pill that was tested for treating Hypoactive Sexual Desire Disorder in women was neither safe nor effective. The voting was rather stark - all 11 panelists decided the side effects were unacceptable, and 10 ruled the pill, known as flibanserin, is not effective. The outcome is hardly surprising, given concerns outlined by FDA reviewers in briefing documents that were released prior to the meeting. The pill did show a statistically difference in generating sexually satisfying experiences compared with a placebo (read the report) - women reported an average of 4.5 per month compared with 2.8 before taking the pill, while the rate jumped to 3.7 for those on placebo. But there was no statistically s... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3676895 Fri, 18 Jun 2010 20:06:59 +0100 3676895 http://www.medworm.com/index.php?rid=3672033&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTTuyvbBKQg8%2F For the past month, The Discovery Channel has been running on its web site a four-part series called ‘Understanding Female Sexual Desire.’ It has a CME label alongside the title - continuing medical education - although the network describes the programming as patient education. The sponsor is noted at the outset and it happens to be Boehringer Ingelheim, which tomorrow hopes to convince an FDA advisory panel to approve a pill to treat a disorder it calls female sexual dysfunction (see this). The series explores Hypoactive Sexual Desire Disorder, which is listed in the Diagnostic and Statistical Manual of Mental Disorders, and Discovery is careful to not mention any drug, including flibanserin, the Boehringer pill, since none is approved to treat the condition. What role, if a... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3672033 Fri, 18 Jun 2010 01:38:37 +0100 3672033 http://www.medworm.com/index.php?rid=3666221&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FjG93Fxo6YPA%2F File this under ‘from hot to cold.’ On the eve of what will be a closely watched and controversial FDA advisory committee meeting on Friday, a team of agency reviewers found the Boehringer Ingelheim pill, which is called flibanserin and was tested to treat Hypoactive Sexual Desire Disorder, failed to meet agreed-upon criteria to establish effectiveness in two company studies. Specifically, there was no statistically significant improvement on the co-primary endpoint of sexual desire, although the pill did show a statistically difference in generating sexually satisfying experiences compared with a placebo (read the report here). The FDA Division of Reproductive/Urologic Drug Products cited several points of “major concern” heading into the meeting: The trials didn&#... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3666221 Wed, 16 Jun 2010 15:45:53 +0100 3666221 http://www.medworm.com/index.php?rid=3665971&cid=t_215911_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fflibanserin-another-pre-fda-approval-drug-hype%2F2010.06.15 This week the FDA will vote on flibanserin, the much-talked-about drug for women with the condition called hypoactive sexual desire disorder or — because everything in sexual health needs an acronym like ED or PE — HSDD. On the eve of the FDA vote, CBS last week ran still another story about flibanserin. This drug has received so much news coverage, you’d think it cures cancer. And CBS did little more than promote the hype even more, saying FDA approval “could translate into a $2 billion market in this country alone” and then failing to challenge the disease-mongering estimate of “10 percent to 30 percent of women” with this condition. It all just goes along with the drug company’s efforts to build a demand before the drug is even approved. (... Better Health blogs http://www.medworm.com/rss/comments.php?id=3665971 Wed, 16 Jun 2010 02:00:41 +0100 3665971 http://www.medworm.com/index.php?rid=3652688&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fv26Nzb8y-10%2F Next week, an FDA advisory committee will meet to review a Boehringer Ingelheim pill to tackle FSD, or female sexual dysfunction. This would be the first such drug for the US market and you will see a lot in the media next week. However, a growing group of psychologists, academics and public health advocates contend FSD isn’t an authentic medical condition, or at least not the sort of problem that should be treated with drugs (one critic is about to publish a book). Bandied about but never proven is the statistic that 43 percent of women suffer from this affliction (background). So we spoke with Leonore Tiefer, a clinical associate professor of psychiatry at the New York University School of Medicine, who heads the NewViewCampaign, a grassroots effort devoted to challenging the ‘me... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3652688 Fri, 11 Jun 2010 15:36:59 +0100 3652688 http://www.medworm.com/index.php?rid=2999485&cid=t_215911_87_f&fid=34872&url=http%3A%2F%2Fwww.blisstree.com%2Fhealthbolt%2Fviagra-for-women-well-sort-of%2F Viagra for men – and the similar drugs that followed after – is a huge, huge money maker for big pharmaceuticals. You have to give them credit. They found a need and they filled it; they rose to the challenge (pun intended ). But now, the target is women. Women do experience sexual dysfunction. Many women would love to have satisfying sex lives but don’t because of various issues. While some researchers are actively working on medications to help women with their sexual desire, some discover a treatment by accident, as did researchers from the University of North Carolina at Chapel Hill School of Medicine The researchers were looking at a medication called flibanserin, an antidepressant. But what the researchers found by pooling information from three separate trials, wa... Healthbolt blogs http://www.medworm.com/rss/comments.php?id=2999485 Tue, 17 Nov 2009 00:53:09 +0100 2999485 http://www.medworm.com/index.php?rid=2013828&cid=t_215911_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F475077892%2F To be specific, this is an hour-long documentary about the race to cure FSD - otherwise known as female sexual dysfunction. In the wake of Viagra and the burgeoning market for impotence pills, CTV, which is Canadian television, commissioned a flick about the efforts by several drugmakers to develop a pill for women. The flick, called Pharma Sutra, airs this Saturday, December 6 at 7 pm EST. The filmmakers follow three drugmakers as they run the “marketing and scientific gauntlet” to cash in on what they were told is an estimated $5 billion “female Viagra” market. And they attempt to answer these questions: Does the future success of the drugs depend on a disease that may have been invented? Or will drugmakers actually meet the genuine needs of millions of women who are suff... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2013828 Thu, 04 Dec 2008 21:51:42 +0100 2013828